Regenerex Pharma, INC

Regenerex Pharma, Inc. announced the resignation of its independent auditor, dbbmckennon, effective August 31, 2026, citing internal decisions, with the company seeking a successor.

Regenerex Pharma provides an update on its SEC reporting status, acknowledging delinquent quarterly reports and outlining efforts to become current.

Regenerex Pharma, Inc. has filed a lawsuit against its former Chief Financial Officer, Kenneth W. Perry, alleging fraud, embezzlement, and destruction of financial records.

Regenerex Pharma, Inc. announced the termination of Chief Financial Officer Kenneth Perry for Cause, effective May 2, 2026, following a review of his conduct.

Regenerex Pharma suspends CFO Kenneth Perry pending review of financial oversight and governance concerns, appointing Don E. Ray as interim CFO.

Regenerex Pharma, Inc. announced a change in its fiscal year end from March 31 to December 31, effective September 22, 2025, to align with calendar year reporting.

Regenerex Pharma reported a significantly increased net loss and substantial cash burn for the six months ended September 30, 2025, with zero revenue, raising substantial doubt about its ability to continue as a going concern.

Regenerex Pharma, Inc. reported a significantly increased net loss of $663,584 for Q2 2025, with zero revenue and substantial doubt about its ability to continue as a going concern.

Regenerex Pharma's Q3 2024 filing reveals a decreased net loss compared to the previous year, as the company continues to develop and market wound care products.

Regenerex Pharma's Q2 2024 results show a decreased net loss compared to the same period last year, as the company continues to develop and market wound care products.

Regenerex Pharma's Q1 2024 filing reveals a widening net loss and continued reliance on debt financing as the company prepares to launch its wound care products.

Regenerex Pharma's Q3 2023 report reveals a significant increase in net loss due to intellectual property acquisition and increased operating expenses.

Regenerex Pharma, Inc. reported a significant net loss for the nine months ended December 31, 2025, and faces substantial doubt about its ability to continue as a going concern, despite strategic initiatives in wound care.

Regenerex Pharma, Inc. reported a reduced net loss for the fiscal year ended March 31, 2025, driven by decreased research and development expenses, while actively pursuing significant strategic partnerships and additional capital to address ongoing liquidity challenges and a going concern doubt.

Regenerex Pharma, a wound care company, reported its full year 2024 results, highlighting a significant net loss and ongoing efforts to launch its wound care products.